When compared to the older aldosterone receptor blocking agent spironolactone, Eplerenone has higher affinity for aldosterone receptor and much less affinity for progesterone receptors (<1%) and androgen receptors (0.1%).20 Recent animal trials have shown that eplerenone reduces the extent of necrosis in myocardial infarction also reduces arteriopathy in hypertensive and heart failure patients.21 Here, NR3C2 is linked to arterial disorder.